Orna Therapeutics
Circular RNA (oRNA) therapeutics platform; merged with Renagade Therapeutics (2024)
Biotech
📍 Watertown, MA
Founded 2019
Current Valuation
Private
PRIVATE
Orna Therapeutics is a Watertown, MA circular-RNA (oRNA) company founded in 2019, developing in vivo CAR (isCAR) and other RNA therapeutics. It raised a $221M Series B in August 2022 alongside a Merck partnership worth up to ~$3.5B. In 2024 Orna acquired the $300M-funded startup Renagade Therapeutics (RNA delivery/editing), with Renagade CEO Amit Munshi (former Arena Pharmaceuticals CEO) taking over as Orna CEO — consolidating a circular-RNA leadership position.
Company Profile
Growth
Consolidated circular-RNA leader after absorbing Renagade (2024)
Last Round
Series B — $221M (Aug 2022) · Lead: MPM BioImpact
Fundraising Status
Series B · $221M · 3y 11mo ago
private1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series B | $221M | Aug 2022 | MPM BioImpact | — |
Founders & Key People
Thomas Barnes
Investors
MPM BioImpact · Merck · ARCH Venture Partners
Products
- oRNA circular RNA platform
- In vivo CAR (isCAR) therapies
- RNA delivery + editing (via Renagade)
Competitors
Sail Biomedicines · Orbital Therapeutics · Therna Biosciences
BiotechRNA TherapeuticsCircular RNATechBio
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.